Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Pharma International Informatics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
J Comp Eff Res. 2021 May;10(7):595-602. doi: 10.2217/cer-2020-0201. Epub 2020 Oct 23.
To investigate the comparative effectiveness of trastuzumab emtansine (T-DM1) in a real-world population of HER2+ metastatic breast cancer (mBC) patients. The Flatiron Health database was used to identify a cohort of HER2+ mBC patients who received first-line trastuzumab treatment and T-DM1 or lapatinib plus chemotherapy as second-line treatment. Overall survival was compared between the two groups. A total of 278 patients with HER2+ mBC received second-line T-DM1 and 34 lapatinib plus chemotherapy. Overall survival was longer in patients treated with T-DM1 than those treated with lapatinib plus chemotherapy (adjusted hazard ratio: 0.56; 95% CI: 0.38-0.85). Real-world data supports the effectiveness of T-DM1 in the second-line treatment of HER2+ mBC patients.
为了研究曲妥珠单抗-美坦新偶联物（T-DM1）在真实世界的 HER2+转移性乳腺癌（mBC）患者人群中的比较疗效。使用 Flatiron Health 数据库确定了一组接受一线曲妥珠单抗治疗且二线治疗接受 T-DM1 或拉帕替尼联合化疗的 HER2+ mBC 患者队列。比较了两组患者的总生存期。共 278 例 HER2+ mBC 患者接受二线 T-DM1 治疗，34 例接受拉帕替尼联合化疗。接受 T-DM1 治疗的患者总生存期长于接受拉帕替尼联合化疗的患者（调整后的危险比：0.56；95%CI：0.38-0.85）。真实世界数据支持 T-DM1 用于二线治疗 HER2+ mBC 患者的有效性。
